563 related articles for article (PubMed ID: 34361762)
1. The Ultrastructure of Tissue Damage by Amyloid Fibrils.
Koike H; Katsuno M
Molecules; 2021 Jul; 26(15):. PubMed ID: 34361762
[TBL] [Abstract][Full Text] [Related]
2. A Review of Novel Agents and Clinical Considerations in Patients With ATTR Cardiac Amyloidosis.
Benbrahim M; Norman K; Sanchorawala V; Siddiqi OK; Hughes D
J Cardiovasc Pharmacol; 2021 May; 77(5):544-548. PubMed ID: 33657048
[TBL] [Abstract][Full Text] [Related]
3. Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments.
Sekijima Y
J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):1036-43. PubMed ID: 25604431
[TBL] [Abstract][Full Text] [Related]
4. Unfolding Cardiac Amyloidosis -From Pathophysiology to Cure.
Ablasser K; Verheyen N; Glantschnig T; Agnetti G; Rainer PP
Curr Med Chem; 2019; 26(16):2865-2878. PubMed ID: 29303069
[TBL] [Abstract][Full Text] [Related]
5. Cardiac Amyloidosis: Overlooked, Underappreciated, and Treatable.
Rubin J; Maurer MS
Annu Rev Med; 2020 Jan; 71():203-219. PubMed ID: 31986086
[TBL] [Abstract][Full Text] [Related]
6. Treatment of cardiac transthyretin amyloidosis: an update.
Emdin M; Aimo A; Rapezzi C; Fontana M; Perfetto F; Seferović PM; Barison A; Castiglione V; Vergaro G; Giannoni A; Passino C; Merlini G
Eur Heart J; 2019 Dec; 40(45):3699-3706. PubMed ID: 31111153
[TBL] [Abstract][Full Text] [Related]
7. The morphology of amyloid fibrils and their impact on tissue damage in hereditary transthyretin amyloidosis: An ultrastructural study.
Koike H; Nishi R; Ikeda S; Kawagashira Y; Iijima M; Sakurai T; Shimohata T; Katsuno M; Sobue G
J Neurol Sci; 2018 Nov; 394():99-106. PubMed ID: 30243104
[TBL] [Abstract][Full Text] [Related]
8. Advances in the diagnosis and treatment of transthyretin amyloidosis with cardiac involvement.
Rigopoulos AG; Ali M; Abate E; Torky AR; Matiakis M; Mammadov M; Melnyk H; Vogt A; de Vecchis R; Bigalke B; Wohlgemuth W; Mavrogeni S; Noutsias M
Heart Fail Rev; 2019 Jul; 24(4):521-533. PubMed ID: 30790171
[TBL] [Abstract][Full Text] [Related]
9. Advances in the treatment of hereditary transthyretin amyloidosis: A review.
Gertz MA; Mauermann ML; Grogan M; Coelho T
Brain Behav; 2019 Sep; 9(9):e01371. PubMed ID: 31368669
[TBL] [Abstract][Full Text] [Related]
10. Treatment of hereditary and acquired forms of transthyretin amyloidosis in the era of personalized medicine: the role of randomized controlled trials.
Buxbaum JN
Amyloid; 2019 Jun; 26(2):55-65. PubMed ID: 30907141
[TBL] [Abstract][Full Text] [Related]
11. Targeted Therapeutics for Transthyretin Amyloid Cardiomyopathy.
Campbell CM; Baiyee CAMT; Almaani S; Bumma N; Sharma N; LoRusso S; Redder E; Bittengle J; Pfund K; Friemer M; Tong M; Kahwash R; Efebera Y; Parikh S; Vallakati A
Am J Ther; 2023 Sep-Oct 01; 30(5):e447-e453. PubMed ID: 37713689
[TBL] [Abstract][Full Text] [Related]
12. A Brief Journey through Protein Misfolding in Transthyretin Amyloidosis (ATTR Amyloidosis).
Gonzalez-Duarte A; Ulloa-Aguirre A
Int J Mol Sci; 2021 Dec; 22(23):. PubMed ID: 34884963
[TBL] [Abstract][Full Text] [Related]
13. Oral Therapy for the Treatment of Transthyretin-Related Amyloid Cardiomyopathy.
Nuvolone M; Girelli M; Merlini G
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555787
[TBL] [Abstract][Full Text] [Related]
14. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
Patil MB; Ghode P; Joshi P
Mini Rev Med Chem; 2024; 24(6):571-587. PubMed ID: 37828667
[TBL] [Abstract][Full Text] [Related]
15. Transthyretin (ATTR) amyloidosis nephropathy: lessons from a TTR stabilizer molecule.
Rocha A; Silva A; Cardoso M; Beirão I; Alves C; Teles P; Coelho T; Lobato L
Amyloid; 2017 Mar; 24(sup1):81-82. PubMed ID: 28434370
[No Abstract] [Full Text] [Related]
16. [Clinical diversity, diagnosis and treatment of hereditary amyloid neuropathy].
Sekijima Y
Rinsho Shinkeigaku; 2014; 54(12):953-6. PubMed ID: 25672679
[TBL] [Abstract][Full Text] [Related]
17. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
[TBL] [Abstract][Full Text] [Related]
18. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
19. Cryo-EM structure of cardiac amyloid fibrils from an immunoglobulin light chain AL amyloidosis patient.
Swuec P; Lavatelli F; Tasaki M; Paissoni C; Rognoni P; Maritan M; Brambilla F; Milani P; Mauri P; Camilloni C; Palladini G; Merlini G; Ricagno S; Bolognesi M
Nat Commun; 2019 Mar; 10(1):1269. PubMed ID: 30894521
[TBL] [Abstract][Full Text] [Related]
20. Developing Therapy for Transthyretin Amyloidosis.
Campbell CM; Zhang K; Lenihan DJ; Witteles R
Am J Med; 2022 Apr; 135 Suppl 1():S44-S48. PubMed ID: 35077703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
